Abstract
INTRODUCTION: The apolipoprotein E gene (APOE) is an established central player in the pathogenesis of Alzheimer's disease (AD), with distinct apoE isoforms exerting diverse effects. apoE influences not only amyloid-beta and tau pathologies but also lipid and energy metabolism, neuroinflammation, cerebral vascular health, and sex-dependent disease manifestations. Furthermore, ancestral background may significantly impact the link between APOE and AD, underscoring the need for more inclusive research. METHODS: In 2023, the Alzheimer's Association convened multidisciplinary researchers at the “AAIC Advancements: APOE” conference to discuss various topics, including apoE isoforms and their roles in AD pathogenesis, progress in apoE-targeted therapeutic strategies, updates on disease models and interventions that modulate apoE expression and function. RESULTS: This manuscript presents highlights from the conference and provides an overview of opportunities for further research in the field. DISCUSSION: Understanding apoE's multifaceted roles in AD pathogenesis will help develop targeted interventions for AD and advance the field of AD precision medicine. Highlights: APOE is a central player in the pathogenesis of Alzheimer's disease. APOE exerts a numerous effects throughout the brain on amyloid-beta, tau, and other pathways. The AAIC Advancements: APOE conference encouraged discussions and collaborations on understanding the role of APOE.
Original language | English |
---|---|
Journal | Alzheimer's and Dementia |
DOIs | |
State | Accepted/In press - 2024 |
Funding
Funders | Funder number |
---|---|
Massachusetts General Hospital Executive Committee | |
BrightFocus foundation postdoctoral fellowship A2021015F | |
Medical Research Council | |
“Training in Translational Research in Alzheimer's and Related Dementias (TRIAD | |
Edward N. and Della L. Thome Memorial Foundation | |
Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation | |
JPB Foundation | |
European Union's Horizon 2020 research and innovation program | |
NIH‐NIDDK | |
Remondi Family Foundation | |
Alzheimer's Drug Discovery Foundation | R01 AG081228, T32 GM008361, R01 AG068395, 1U19AG069701 |
Alzheimer's Drug Discovery Foundation | |
NIA | R41 AG077992, F32AG08483, R01AG061186, T32 AG078110, R01HL149685, 23AARG‐1026607, R01 AG057522 |
NIH NIA | R01AG062837, T32AG058518 |
Cure Alzheimer's Fund | RF1AG078362, R01AG66395, U01AG058635, R21AG056518, R01AG067063, RF1AG076124, GC‐201711‐2014197, P30AG066530, R01AG055770, RF1AG046205, R01AG054434, U54NS110435 |
Cure Alzheimer's Fund | |
NIH‐NIA | U19 AG069701 |
U.S. Department of Defense | W81XWH‐21‐1‐0093 |
U.S. Department of Defense | |
National Institute of Neurological Disorders and Stroke | UH3 NS100121, RF1 NS110048 |
National Institute of Neurological Disorders and Stroke | |
Alzheimer's Association | AARF‐20‐683984 |
Alzheimer's Association | |
BrightFocus Foundation | P01AG073082, R01AG062550, R56AG081417 NIH U19AG069701, R01AG081421, A2022010F, NS126467 ApoE4, R01AG080589, R01AG060056 |
BrightFocus Foundation | |
National Institute on Aging | RF1AG077627, R01 AG054671, R01AG059737, U19AG069701, U01AG058589, RF1AG067194 |
National Institute on Aging | |
NuBrain Consortium | MR/T001852/1 |
Alzheimer's Disease | U54 AG065181, U54AG054345, GM131839‐03, RF1 AG074566 |
National Institutes of Health | DP5 OD019833 |
National Institutes of Health | |
National Institute of General Medical Sciences | P20GM148326 |
National Institute of General Medical Sciences | |
ECOR | 3RF1NS118558, P30EY003790, 5R01AG070830, T32AG05851804 |
CNPq | 7DP5OD028133, 304746/2022‐3 |
NSF | R01AG082362, P30AG066512, R01AG083941, K01AG062683, R56AG078733, P01AG060882.R, DGE‐1745038 |
H2020 Marie Skłodowska-Curie Actions | 890650 |
H2020 Marie Skłodowska-Curie Actions |
Keywords
- APOE
- Alzheimer's disease
- apolipoprotein E
- conference proceedings
- dementia
- lipids
- microglia
- neuroinflammation
- risk factor
- therapeutics
- vasculature